Design and conduct of early clinical studies of two or more targeted anticancer therapies: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies-Reference-Cited by-同舟云学术

Design and conduct of early clinical studies of two or more targeted anticancer therapies: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies

Published:2013-05 Issue:8 Volume:49 Page:1808-1814
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Seymour Lesley K.,Calvert A. Hilary,Lobbezoo Marinus W.,Eisenhauer Elizabeth A.,Giaccone Giuseppe

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference29 articles.

1. Emerging trends in US oncological approvals: a 13-year review (1999–2011);Huang;Drug Inf J,2012

2. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer;Wang;J Cancer Res Clin Oncol,2012

3. Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma;Aziz;Clin Cancer Res,2010

4. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors;De Raedt;Cancer Cell,2011

5. Overcoming resistance to molecularly targeted anticancer therapies: rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies;Tortora;Drug Resist Update,2007

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Testing new anticancer drugs before curative locoregional therapies: MDICT 2024 recommendations;ESMO Open;2024-08

2. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022;Annals of Oncology;2023-01

3. Comparison of Various Phase I Combination Therapy Designs in Oncology for Evaluation of Early Tumor Shrinkage Using Simulations;CPT: Pharmacometrics & Systems Pharmacology;2020-11-05

4. Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT);Clinical Cancer Research;2020-02-21

5. Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies;Annals of Oncology;2018-11